Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

31.93
+0.04000.13%
Volume:649.52K
Turnover:20.66M
Market Cap:1.83B
PE:12.18
High:32.45
Open:32.14
Low:31.40
Close:31.89
Loading ...

Harmony Biosciences: Sales Agreement Prospectus Supplement Covering Offering of up to $200 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
26 Feb

Stock Track | Harmony Biosciences (HRMY) Soars 5.02% on Strong Q4 Results, Pitolisant Patent Win, Pipeline Progress

Stock Track
·
26 Feb

Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
26 Feb

Harmony Biosciences Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-  Eli Lilly, Krispy Kreme, PayPal

Reuters
·
25 Feb

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates

Zacks
·
25 Feb

Harmony Biosciences Price Target Maintained With a $50.00/Share by Needham

Dow Jones
·
25 Feb

BUZZ-Harmony Biosciences rises on quarterly profit and sales beat

Reuters
·
25 Feb

Harmony Biosciences' Q4 Adjusted Earnings, Net Product Revenue Rise

MT Newswires Live
·
25 Feb

Earnings Flash (HRMY) Harmony Biosciences Posts Q4 Net Product Revenue $201.3M, vs. FactSet Est of $201M

MT Newswires Live
·
25 Feb

Harmony Biosciences Q4 Adj $1.08 Beats $0.74 Estimate, Sales $201.27M Beat $201.25M Estimate

Benzinga
·
25 Feb

BRIEF-Harmony Biosciences Q4 Net Income USD 49.475 Million

Reuters
·
25 Feb

Harmony Biosciences: Reiterates 2025 Net Revenue Guidance

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Q4 Operating Income USD 55.727 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Adj EPS $1.08

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc Q4 Shr View $0.74, REV View $201.0 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Net Product Revenues $201.3 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc FY2025 REV View $848.5 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Business Wire
·
25 Feb

Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now?

Insider Monkey
·
25 Feb